Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VF Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while VF Corp trades at $16 (market cap $6.45B). The key difference: VF Corp is the larger of the two by market cap, and VF Corp pays a 2.19% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VFC | |
|---|---|---|
Market Cap | $4.49B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $21.55 |
52-Week Low | $20.06 | $11.66 |
Enterprise Value | $3.69B | $10.60B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VFC trades at $16.45, up 0.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings showed a Q1 2026 miss after two prior beats, while revenue declined to $9.50B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M. Analyst consensus is mixed with a $20.00 price target, and news highlights focus on turnaround progress and debt reduction.
VFC's outlook hinges on executing its brand turnaround, particularly at Vans, with guided revenue growth for 2027 offering potential upside. Risks include weak consumer confidence and high leverage, though deleveraging efforts are underway. The stock presents a value opportunity with a low P/S of 0.68, but investors face near-term volatility from earnings uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
